Aspirin in Primary and Secondary Prevention of Cardiovascular Disease

Area of Science:

• Cardiology
• Preventive Medicine
• Pharmacology

Background:

• Aspirin is widely used for cardiovascular disease treatment, with proven mortality benefits in patients with existing conditions.
• The efficacy of aspirin for primary prevention in individuals without established cardiovascular disease has been debated.
• Recent large-scale trials have re-evaluated aspirin's role in primary cardiovascular prevention.

Purpose of the Study:

• To assess the benefits and risks of aspirin therapy for primary prevention of cardiovascular disease.
• To synthesize evidence from recent randomized controlled trials on aspirin's primary preventive role.
• To inform clinical guidelines regarding aspirin use in individuals at risk for cardiovascular events.

Main Methods:

• Review of recent randomized controlled trials (ARRIVE, ASCEND, ASPREE) evaluating aspirin for primary cardiovascular prevention.
• Analysis of data on cardiovascular event rates and mortality in aspirin versus placebo groups.
• Assessment of bleeding events as a key safety outcome.

Main Results:

• Three major trials (ARRIVE, ASCEND, ASPREE) in 2018 showed modest to no significant benefit of aspirin in preventing cardiovascular events or mortality for primary prevention.
• These trials consistently identified an increased risk of bleeding events in patients taking aspirin for primary prevention.
• The overall benefit-risk profile suggests limited utility for routine primary prevention.

Conclusions:

• Current evidence does not robustly support the use of aspirin for primary prevention of cardiovascular disease in most individuals.
• The increased risk of bleeding associated with aspirin therapy outweighs the modest or absent benefits for primary prevention.
• Clinical decisions regarding aspirin for primary prevention should be individualized based on a careful assessment of risks and benefits.